PDF(Pubmed)
Abstract：
Atopic dermatitis (AD) is a chronic immune-mediated disease characterized by intense pruritis, causing inflammation, itching, and redness of the skin. Dupilumab is a human monoclonal antibody that has been approved for the treatment of atopic dermatitis. It has also been linked with various adverse effects, most of them confined to the injection site. Café-au-lait-macules are benign pigmented lesions of the skin, usually seen in people with genetic disorders. We present a case of café-au-lait macules as an adverse effect of dupilumab therapy in a patient with atopic dermatitis. The patient in this case had been receiving dupilumab therapy for atopic dermatitis. The eczematous lesions had seen improvement; however, the patient presented with CALMs on follow-up, which seem to be linked with dupilumab therapy.
摘要：
特应性皮炎（AD）是一种慢性免疫介导的疾病，其特征是剧烈瘙痒，引起炎症，瘙痒,皮肤发红。Dupilumab是一种人单克隆抗体，已被批准用于治疗特应性皮炎。它还与各种不利影响有关，他们中的大多数局限于注射部位。Café-au-lait-macules是皮肤的良性色素沉着病变，通常见于患有遗传性疾病的人。我们介绍了一例café-au-lait黄斑作为dupilumab治疗特应性皮炎患者的不良反应。在这种情况下，患者一直在接受dupilumab治疗特应性皮炎。湿疹性病变有所改善；然而，患者在随访中接受了CALM，这似乎与dupilumab治疗有关。
